463 related articles for article (PubMed ID: 12675140)
1. Cholinesterases: new roles in brain function and in Alzheimer's disease.
Giacobini E
Neurochem Res; 2003 Apr; 28(3-4):515-22. PubMed ID: 12675140
[TBL] [Abstract][Full Text] [Related]
2. Cholinesterase inhibitors: new roles and therapeutic alternatives.
Giacobini E
Pharmacol Res; 2004 Oct; 50(4):433-40. PubMed ID: 15304240
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease?
Giacobini E
Drugs Aging; 2001; 18(12):891-8. PubMed ID: 11888344
[TBL] [Abstract][Full Text] [Related]
4. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
5. A new therapeutic target in Alzheimer's disease treatment: attention to butyrylcholinesterase.
Greig NH; Utsuki T; Yu Q; Zhu X; Holloway HW; Perry T; Lee B; Ingram DK; Lahiri DK
Curr Med Res Opin; 2001; 17(3):159-65. PubMed ID: 11900310
[TBL] [Abstract][Full Text] [Related]
6. Cholinesterase inhibitors modify the activity of intrinsic cardiac neurons.
Darvesh S; Arora RC; Martin E; Magee D; Hopkins DA; Armour JA
Exp Neurol; 2004 Aug; 188(2):461-70. PubMed ID: 15246845
[TBL] [Abstract][Full Text] [Related]
7. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer' disease.
Giacobini E
J Neural Transm Suppl; 2002; (62):181-7. PubMed ID: 12456062
[TBL] [Abstract][Full Text] [Related]
8. Cholinesterases in cardiac ganglia and modulation of canine intrinsic cardiac neuronal activity.
Darvesh S; MacDonald SE; Losier AM; Martin E; Hopkins DA; Armour JA
J Auton Nerv Syst; 1998 Jul; 71(2-3):75-84. PubMed ID: 9760044
[TBL] [Abstract][Full Text] [Related]
9. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy.
Greig NH; Lahiri DK; Sambamurti K
Int Psychogeriatr; 2002; 14 Suppl 1():77-91. PubMed ID: 12636181
[TBL] [Abstract][Full Text] [Related]
10. Is anti-cholinesterase therapy of Alzheimer's disease delaying progression?
Giacobini E
Aging (Milano); 2001 Jun; 13(3):247-54. PubMed ID: 11442306
[TBL] [Abstract][Full Text] [Related]
11. Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies.
Darreh-Shori T; Soininen H
Curr Alzheimer Res; 2010 Feb; 7(1):67-73. PubMed ID: 20205672
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
[TBL] [Abstract][Full Text] [Related]
13. A review on cholinesterase inhibitors for Alzheimer's disease.
Anand P; Singh B
Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
[TBL] [Abstract][Full Text] [Related]
14. Kinetic analysis of the inhibition of human butyrylcholinesterase with cymserine.
Kamal MA; Al-Jafari AA; Yu QS; Greig NH
Biochim Biophys Acta; 2006 Feb; 1760(2):200-6. PubMed ID: 16309845
[TBL] [Abstract][Full Text] [Related]
15. Cholinesterase inhibition in Alzheimer's disease: is specificity the answer?
Macdonald IR; Rockwood K; Martin E; Darvesh S
J Alzheimers Dis; 2014; 42(2):379-84. PubMed ID: 24898642
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of human serum butyrylcholinesterase and its inhibition by a novel experimental Alzheimer therapeutic, bisnorcymserine.
Kamal MA; Klein P; Yu QS; Tweedie D; Li Y; Holloway HW; Greig NH
J Alzheimers Dis; 2006 Sep; 10(1):43-51. PubMed ID: 16988481
[TBL] [Abstract][Full Text] [Related]
17. Cholinesterases: roles in the brain during health and disease.
Ballard CG; Greig NH; Guillozet-Bongaarts AL; Enz A; Darvesh S
Curr Alzheimer Res; 2005 Jul; 2(3):307-18. PubMed ID: 15974896
[TBL] [Abstract][Full Text] [Related]
18. [Cholinesterases and their importance in the etiology, diagnosis and therapy of Alzheimer's disease].
Patocka J; Strunecká A; Rípová D
Cesk Fysiol; 2001 Feb; 50(1):4-10. PubMed ID: 11268561
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of human serum butyrylcholinesterase inhibition by a novel experimental Alzheimer therapeutic, dihydrobenzodioxepine cymserine.
Kamal MA; Klein P; Luo W; Li Y; Holloway HW; Tweedie D; Greig NH
Neurochem Res; 2008 May; 33(5):745-53. PubMed ID: 17985237
[TBL] [Abstract][Full Text] [Related]
20. Status of acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease and type 2 diabetes mellitus.
Mushtaq G; Greig NH; Khan JA; Kamal MA
CNS Neurol Disord Drug Targets; 2014; 13(8):1432-9. PubMed ID: 25345511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]